In the orthotopic xenograft tumor model, the positive rates of LYVE-1, VEGF-C, and VEGFR-3 in the control group were 29.00 ± 1.42%, 45.41 ± 0.93%, and 51.80 ± 0.19%, respectively, and those in the PZH group were 19.25 ± 1.25%, 27.55 ± 1.52%, and 31.61 ± 1.15%, respectively. The gene discussed is VEGFC; the disease is neoplasm.